Botulism screening

Botulism Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Botulism from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Botulism screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Botulism screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Botulism screening
CDC on Botulism screening
Botulism screening in the news
Blogs on Botulism screening
Directions to Hospitals Treating Botulism
Risk calculators and risk factors for Botulism screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Tarek Nafee, M.D. [2], Keanu Ngo[3]

Overview

There is no screening test for botulism and no professional-society or U.S. Preventive Services Task Force (USPSTF) recommendation for screening asymptomatic individuals; USPSTF has never issued a botulism screening statement. Botulism is a rare, acute, non-communicable intoxication that does not have an asymptomatic or preclinical detectable phase amenable to screening; it therefore fails standard screening (Wilson-Jungner) criteria. Instead of screening, the relevant public-health activities are mandatory case reporting, surveillance, rapid clinical recognition, and outbreak case-finding, with close observation (not laboratory screening) of asymptomatic exposed persons.

Why routine screening does not apply

Botulism does not meet the conditions that make screening useful:

• No detectable asymptomatic/latent phase in which early detection would change outcome; disease is defined by acute neurologic signs.
• Very low prevalence (a few hundred U.S. cases/year across all forms), which would render any screening test's positive predictive value negligible.
• Confirmatory tests are slow and reference-laboratory–based (mouse bioassay, mass spectrometry, NAAT for BoNT genes) and are designed to confirm clinically suspected disease, not to screen well people.
• Diagnosis is clinical and treatment is empiric: antitoxin is given on clinical suspicion without waiting for testing, so a screening paradigm offers no benefit.

What replaces screening: surveillance and case detection

• Mandatory reporting. Botulism of any type is a nationally notifiable condition; in most U.S. jurisdictions a case suspected on clinical grounds alone must, by law, be reported immediately (by telephone) to local/state health authorities. State health departments maintain 24-hour service, and the CDC Clinical Emergency Botulism Service is available at 770-488-7100.
• National surveillance. Since 1973 the CDC has maintained national botulism surveillance; because antitoxin is released only through public-health channels, nearly all recognized cases are captured, supporting outbreak detection and trend monitoring.
• Heightened clinical detection. CDC outbreak guidance provides a diagnostic tool and urges clinicians to consider botulism in patients labeled as myasthenia gravis, Guillain-Barré syndrome, or isolated symmetric facial/bulbar weakness, and to watch for early respiratory failure—an approach that functions as active case detection during outbreaks.
• Newborn screening. Botulism is not included in newborn screening programs; infant botulism is identified by clinical recognition and confirmatory testing of symptomatic infants, not by screening.
• Outbreak case-finding. Once one case is identified, public-health investigation actively seeks additional exposed persons (e.g., shared food source), collects implicated foods, and obtains serum/stool from co-exposed symptomatic persons—case-finding, not asymptomatic screening.

Management of asymptomatic exposed persons

Asymptomatic persons known to have ingested a food containing (or suspected of containing) botulinum toxin should not undergo prophylactic antitoxin; instead they require close medical observation in nonsolitary settings for evolving signs. This is active surveillance of a defined exposed cohort, distinct from population screening.

Relationship to prevention

Because there is no screening, risk reduction depends on primary prevention (no honey before 12 months; safe home-canning/pressure processing; adequate refrigeration of processed foods; harm reduction for injection drug use), which is addressed in the Primary Prevention microchapter and only cross-referenced here.

Clinically actionable points

• Do not order botulism toxin testing to screen asymptomatic people; test only symptomatic patients, and treat on clinical suspicion without awaiting results.
• Report any suspected case immediately to the state health department (or CDC after hours); reporting substitutes for screening as the population-level safeguard.
• Observe, do not prophylactically treat, asymptomatic exposed persons in a monitored, nonsolitary setting.